Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
| ▸ | XIAP | P98170 | 1/20 | 0.65 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.65 |
| ▸ | LTA4H | P09960 | 1/20 | 0.61 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.56 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.51 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.50 |
| ▸ | PPARG | P37231 | 7/20 | 0.50 |
| ▸ | PPARD | Q03181 | 7/20 | 0.50 |
| ▸ | PPARA | Q07869 | 7/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | FABP4 | P15090 | 2/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Phenylalanine SCHEMBL598090 | 1.00 | ALPI (0.65) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Dodecanoate SCHEMBL599338 | 1.00 | ALPI (0.65) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Decanoic Acid SCHEMBL17667545 | 1.00 | ALPI (0.65) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Phenylalanine SCHEMBL598091 | 1.00 | ALPI (0.65) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Tetradecane SCHEMBL21002171 | 0.92 | SLC7A5 (0.76) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Dl-Phenylalanine SCHEMBL15656237 | 0.91 | SLC7A5 (0.79) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Phenylalanine SCHEMBL15656236 | 0.91 | SLC7A5 (0.79) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Dodecanoate SCHEMBL2779341 | 0.90 | ALPI (0.52) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Tyrosine SCHEMBL5605357 | 0.89 | SLC7A5 (0.67) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Stearic Acid SCHEMBL4276901 | 0.89 | SLC7A5 (0.67) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948199-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS | IDEXX LAB INC (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-1960415-B1 | Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same | IDEXX LAB INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8293253-B2 | Compositions for controlled delivery of pharmaceutically active compounds | IDEXX LABORATORIES, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8114440-B2 | Pharmaceutical compositions for the administration of aptamers | IDEXX LABORATORIES INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8017159-B2 | Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same | IDEXX LABORATORIES, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20100240741-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS | IDEXX LABORATORIES, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100204303-A1 | Pharmaceutical Compositions for Administering Oligonucleotides | IDEXX LABORATORIES, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-7754679-B2 | Pharmaceutical compositions for the administration of aptamers | IDEXX LABORATORIES, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| EP-2197454-A1 | PHARMACEUTICAL COMPOSITIONS FOR ADMINISTERING OLIGONUCLEOTIDES | IDEXX Laboratories Inc (US) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009042625-A1 | PHARMACEUTICAL COMPOSITIONS FOR ADMINISTERING OLIGONUCLEOTIDES | IDEXX LABORATORIES, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| EP-1960415-A2 | PHOSPHOLIPID GEL COMPOSITIONS FOR DELIVERY OF APTAMERS AND METHODS OF TREATING CONDITIONS USING SAME | IDEXX Laboratories Inc (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1948199-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS | IDEXX Laboratories Inc (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1804771-A2 | COMPOSITIONS FOR CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS | IDEXX LABORATORIES, INC. (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2007058800-A2 | PHOSPHOLIPID GEL COMPOSITIONS FOR DELIVERY OF APTAMERS AND METHODS OF TREATING CONDITIONS USING SAME | IDEXX LABORATORIES INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058801-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS | IDEXX LABORATORIES INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070110827-A1 | Pharmaceutical compositions for the administration of aptamers | IDEXX LABORATORIES INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070110775-A1 | Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same | IDEXX LABORATORIES INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070111969-A1 | Pharmaceutical compositions for the administration of aptamers | IDEXX LABORATORIES INC. | 2007-05-17 | — | — | US | disclosed |
| WO-2006050002-A2 | COMPOSITIONS FOR CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS | IDEXX LABORATORIES, INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20060093632-A1 | Compositions for controlled delivery of pharmaceutically active compounds | IDEXX LABORATORIES, INC. | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060093632-A1 | Compositions for controlled delivery of pharmaceutically active compounds | LIPA, CEL, LPXN | ALPI 194/4885PKM 1626/4885PTGS1 313/4885 |
| US-20100240741-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS | PHOSPHO1, SGMS1, PCYT1A | ALPI 1073/4885PKM 2112/4885PTGS1 4398/4885 |
| US-20070111969-A1 | Pharmaceutical compositions for the administration of aptamers | PHOSPHO1, SGMS1, PCYT1A | ALPI 1073/4885PKM 2112/4885PTGS1 4398/4885 |
| US-20100204303-A1 | Pharmaceutical Compositions for Administering Oligonucleotides | SLCO2A1, SLCO1A2, SLCO2B1 | ALPI 439/4885PKM 4011/4885PTGS1 3986/4885 |
| US-20070110827-A1 | Pharmaceutical compositions for the administration of aptamers | PHOSPHO1, SGMS1, PCYT1A | ALPI 1073/4885PKM 2112/4885PTGS1 4398/4885 |
| US-20070110775-A1 | Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same | ANXA6, ANXA2, PLTP | ALPI 1143/4885PKM 2803/4885PTGS1 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.